Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 11 | 2019 | 848 | 0.910 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2017 | 38 | 0.510 |
Why?
|
| Spinal Stenosis | 1 | 2017 | 50 | 0.500 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2014 | 270 | 0.420 |
Why?
|
| Paclitaxel | 2 | 2014 | 488 | 0.420 |
Why?
|
| Glioma | 3 | 2014 | 321 | 0.400 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 99 | 0.400 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 587 | 0.380 |
Why?
|
| Ophthalmoplegia | 1 | 2012 | 12 | 0.370 |
Why?
|
| Orbit | 1 | 2012 | 38 | 0.370 |
Why?
|
| Head Injuries, Penetrating | 1 | 2012 | 67 | 0.340 |
Why?
|
| Wounds, Gunshot | 1 | 2012 | 121 | 0.320 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 1192 | 0.320 |
Why?
|
| Radiosurgery | 2 | 2024 | 316 | 0.250 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2006 | 22 | 0.250 |
Why?
|
| Neurofibromatosis 1 | 1 | 2006 | 45 | 0.240 |
Why?
|
| Drug Implants | 3 | 2002 | 40 | 0.230 |
Why?
|
| Meningioma | 1 | 2024 | 68 | 0.200 |
Why?
|
| Meningeal Neoplasms | 1 | 2024 | 73 | 0.200 |
Why?
|
| Nevus, Blue | 1 | 2003 | 5 | 0.200 |
Why?
|
| Nitric Oxide Donors | 1 | 2002 | 13 | 0.190 |
Why?
|
| Hemangioma, Cavernous | 1 | 2003 | 69 | 0.190 |
Why?
|
| Vasospasm, Intracranial | 1 | 2002 | 36 | 0.190 |
Why?
|
| Polyamines | 1 | 2002 | 38 | 0.190 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 1079 | 0.190 |
Why?
|
| Oligodendroglioma | 2 | 2019 | 45 | 0.180 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2002 | 154 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2017 | 591 | 0.160 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2019 | 4 | 0.160 |
Why?
|
| Rats, Inbred F344 | 2 | 2014 | 165 | 0.150 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2019 | 101 | 0.150 |
Why?
|
| Drug Delivery Systems | 2 | 2014 | 198 | 0.150 |
Why?
|
| Endoscopy | 3 | 2016 | 374 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2016 | 3639 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2003 | 621 | 0.140 |
Why?
|
| Craniotomy | 3 | 2015 | 97 | 0.140 |
Why?
|
| Kisspeptins | 1 | 2017 | 4 | 0.140 |
Why?
|
| Cerebral Angiography | 2 | 2012 | 217 | 0.130 |
Why?
|
| Chemokine CXCL12 | 1 | 2017 | 38 | 0.130 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 2017 | 19 | 0.130 |
Why?
|
| Cervical Cord | 1 | 2017 | 16 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 2383 | 0.130 |
Why?
|
| Humans | 28 | 2024 | 95800 | 0.130 |
Why?
|
| Astrocytes | 1 | 2017 | 151 | 0.130 |
Why?
|
| Cauda Equina | 2 | 2007 | 13 | 0.130 |
Why?
|
| Nose Neoplasms | 1 | 2016 | 36 | 0.130 |
Why?
|
| Gout | 1 | 2017 | 75 | 0.120 |
Why?
|
| Paranasal Sinuses | 1 | 2016 | 62 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 166 | 0.120 |
Why?
|
| Enuresis | 3 | 2000 | 4 | 0.120 |
Why?
|
| Microspheres | 2 | 2014 | 105 | 0.120 |
Why?
|
| Rats | 4 | 2014 | 4154 | 0.120 |
Why?
|
| Autophagy | 1 | 2017 | 175 | 0.120 |
Why?
|
| Paresis | 1 | 2015 | 19 | 0.120 |
Why?
|
| Syndrome | 2 | 2015 | 450 | 0.110 |
Why?
|
| Male | 15 | 2024 | 45686 | 0.110 |
Why?
|
| Reflex, Startle | 3 | 2000 | 32 | 0.110 |
Why?
|
| Cranial Irradiation | 1 | 2014 | 41 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 91 | 0.110 |
Why?
|
| Propofol | 1 | 2014 | 95 | 0.100 |
Why?
|
| Hypertriglyceridemia | 1 | 2014 | 72 | 0.100 |
Why?
|
| Chemokines | 1 | 2013 | 77 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 411 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 2777 | 0.100 |
Why?
|
| Aspartic Acid | 1 | 2013 | 67 | 0.100 |
Why?
|
| Motor Cortex | 1 | 2015 | 215 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 366 | 0.100 |
Why?
|
| Seizures | 1 | 2015 | 331 | 0.090 |
Why?
|
| Carotid Artery Injuries | 1 | 2012 | 22 | 0.090 |
Why?
|
| Maxillary Sinus | 1 | 2012 | 21 | 0.090 |
Why?
|
| Carotid Artery, Internal | 1 | 2012 | 70 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 2773 | 0.090 |
Why?
|
| Propionibacterium acnes | 1 | 2011 | 8 | 0.090 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 156 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 557 | 0.090 |
Why?
|
| Osteomyelitis | 1 | 2011 | 57 | 0.090 |
Why?
|
| Hypertension | 1 | 2017 | 774 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2024 | 7215 | 0.090 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2011 | 52 | 0.090 |
Why?
|
| Adult | 7 | 2024 | 28578 | 0.080 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2010 | 4 | 0.080 |
Why?
|
| Meningocele | 1 | 2010 | 6 | 0.080 |
Why?
|
| Occipital Bone | 1 | 2010 | 15 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2000 | 188 | 0.080 |
Why?
|
| Carbocyanines | 2 | 2007 | 18 | 0.080 |
Why?
|
| Scorpion Venoms | 2 | 2007 | 25 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 1739 | 0.080 |
Why?
|
| Animals | 9 | 2017 | 28889 | 0.080 |
Why?
|
| Choroid Plexus | 1 | 2009 | 16 | 0.080 |
Why?
|
| Back Injuries | 1 | 2009 | 6 | 0.080 |
Why?
|
| Pneumocephalus | 1 | 2009 | 12 | 0.080 |
Why?
|
| Wounds, Stab | 1 | 2009 | 12 | 0.080 |
Why?
|
| Third Ventricle | 1 | 2009 | 14 | 0.080 |
Why?
|
| Liver | 1 | 2014 | 1231 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 382 | 0.070 |
Why?
|
| Cysts | 1 | 2009 | 104 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2011 | 237 | 0.070 |
Why?
|
| Hydrocephalus | 1 | 2009 | 108 | 0.070 |
Why?
|
| Brain Diseases | 1 | 2009 | 192 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 2 | 2007 | 443 | 0.070 |
Why?
|
| Female | 11 | 2024 | 49872 | 0.070 |
Why?
|
| Subdural Effusion | 1 | 2007 | 2 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 1346 | 0.060 |
Why?
|
| Brain | 3 | 2012 | 2480 | 0.060 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2006 | 45 | 0.060 |
Why?
|
| Neoplasms | 2 | 2013 | 3240 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 3904 | 0.060 |
Why?
|
| Middle Aged | 6 | 2024 | 28208 | 0.060 |
Why?
|
| Ferric Compounds | 1 | 2005 | 41 | 0.060 |
Why?
|
| Nanotechnology | 1 | 2005 | 73 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1670 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2015 | 2592 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 3155 | 0.050 |
Why?
|
| Neurosurgical Procedures | 3 | 2014 | 356 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2005 | 376 | 0.050 |
Why?
|
| Intelligence | 2 | 2000 | 73 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2024 | 9167 | 0.050 |
Why?
|
| Cisterna Magna | 1 | 2002 | 11 | 0.050 |
Why?
|
| Polyvinyls | 1 | 2002 | 21 | 0.050 |
Why?
|
| Basilar Artery | 1 | 2002 | 40 | 0.050 |
Why?
|
| Bone Marrow Diseases | 1 | 2002 | 37 | 0.050 |
Why?
|
| Carmustine | 1 | 2002 | 71 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 117 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2002 | 111 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2002 | 270 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2002 | 1965 | 0.040 |
Why?
|
| Guanine | 1 | 2002 | 207 | 0.040 |
Why?
|
| Rabbits | 1 | 2002 | 639 | 0.040 |
Why?
|
| Habituation, Psychophysiologic | 2 | 1999 | 14 | 0.040 |
Why?
|
| Reoperation | 2 | 2015 | 707 | 0.040 |
Why?
|
| Aged | 4 | 2024 | 20848 | 0.040 |
Why?
|
| Polymers | 1 | 2001 | 220 | 0.040 |
Why?
|
| Recurrence | 2 | 2015 | 1211 | 0.040 |
Why?
|
| Neural Inhibition | 1 | 1999 | 108 | 0.040 |
Why?
|
| Survival Rate | 1 | 2002 | 1971 | 0.040 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2017 | 11 | 0.030 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2017 | 12 | 0.030 |
Why?
|
| Cues | 1 | 1999 | 189 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2017 | 88 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 1997 | 56 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 84 | 0.030 |
Why?
|
| Nasal Obstruction | 1 | 2016 | 21 | 0.030 |
Why?
|
| Arousal | 1 | 1997 | 173 | 0.030 |
Why?
|
| Epistaxis | 1 | 2016 | 20 | 0.030 |
Why?
|
| Microglia | 1 | 2017 | 124 | 0.030 |
Why?
|
| Indazoles | 1 | 2016 | 61 | 0.030 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2016 | 92 | 0.030 |
Why?
|
| Headache | 1 | 2016 | 82 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2024 | 10273 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 528 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 9873 | 0.030 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2015 | 36 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2534 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2015 | 303 | 0.030 |
Why?
|
| Neuroma, Acoustic | 1 | 2014 | 21 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 73 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2014 | 75 | 0.030 |
Why?
|
| Anesthetics, Intravenous | 1 | 2014 | 43 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2016 | 337 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2014 | 63 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2015 | 397 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 386 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2016 | 327 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2014 | 101 | 0.030 |
Why?
|
| Language | 1 | 2015 | 162 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 315 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2014 | 275 | 0.020 |
Why?
|
| Infant | 2 | 2010 | 3360 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 857 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 517 | 0.020 |
Why?
|
| Child | 5 | 2007 | 7618 | 0.020 |
Why?
|
| Oncolytic Virotherapy | 1 | 2012 | 43 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 299 | 0.020 |
Why?
|
| Mice | 3 | 2017 | 12537 | 0.020 |
Why?
|
| RNA Stability | 1 | 2012 | 97 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2015 | 594 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 2605 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 325 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 7026 | 0.020 |
Why?
|
| Cefazolin | 1 | 2011 | 8 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2010 | 3970 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 446 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2011 | 67 | 0.020 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2010 | 4 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 2010 | 22 | 0.020 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2010 | 17 | 0.020 |
Why?
|
| Tissue Adhesives | 1 | 2010 | 24 | 0.020 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2010 | 28 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2010 | 51 | 0.020 |
Why?
|
| Cartilage | 1 | 2010 | 116 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2012 | 382 | 0.020 |
Why?
|
| Septum Pellucidum | 1 | 2009 | 3 | 0.020 |
Why?
|
| Spinal Canal | 1 | 2009 | 6 | 0.020 |
Why?
|
| Lateral Ventricles | 1 | 2009 | 12 | 0.020 |
Why?
|
| Microsurgery | 1 | 2010 | 99 | 0.020 |
Why?
|
| Emphysema | 1 | 2009 | 24 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1559 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2011 | 298 | 0.020 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 238 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 376 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2012 | 556 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 1021 | 0.020 |
Why?
|
| Spinal Diseases | 1 | 2009 | 99 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1425 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2012 | 454 | 0.020 |
Why?
|
| Acoustic Stimulation | 2 | 1999 | 131 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2007 | 48 | 0.020 |
Why?
|
| Photons | 1 | 2007 | 49 | 0.020 |
Why?
|
| Klippel-Feil Syndrome | 1 | 2006 | 1 | 0.020 |
Why?
|
| Torticollis | 1 | 2006 | 12 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 2480 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1535 | 0.020 |
Why?
|
| Growth | 1 | 2006 | 43 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2089 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 3990 | 0.020 |
Why?
|
| Postural Balance | 1 | 2006 | 53 | 0.020 |
Why?
|
| Scoliosis | 1 | 2006 | 43 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 21 | 0.020 |
Why?
|
| Body Height | 1 | 2006 | 108 | 0.020 |
Why?
|
| Comorbidity | 2 | 2000 | 1011 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 847 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 262 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 630 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 68 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 354 | 0.010 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 138 | 0.010 |
Why?
|
| Dogs | 1 | 2006 | 718 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1463 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2006 | 201 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 286 | 0.010 |
Why?
|
| Nanostructures | 1 | 2005 | 89 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2005 | 187 | 0.010 |
Why?
|
| Risk Factors | 1 | 2014 | 5961 | 0.010 |
Why?
|
| Peritoneal Cavity | 1 | 2002 | 20 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2002 | 51 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 3581 | 0.010 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2002 | 25 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2005 | 490 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2005 | 323 | 0.010 |
Why?
|
| Necrosis | 1 | 2002 | 210 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 317 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 2002 | 118 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 1124 | 0.010 |
Why?
|
| Pleasure-Pain Principle | 1 | 1997 | 2 | 0.010 |
Why?
|
| Child Development | 1 | 1999 | 174 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1999 | 908 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 1063 | 0.010 |
Why?
|
| Heart Rate | 1 | 1997 | 518 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1999 | 1957 | 0.010 |
Why?
|
| Attention | 1 | 1997 | 413 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2000 | 2473 | 0.010 |
Why?
|